CRBP Stock Overview
A biopharmaceutical company, develops products to defeat serious illness.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Corbus Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.96 |
| 52 Week High | US$50.42 |
| 52 Week Low | US$3.03 |
| Beta | 2.47 |
| 1 Month Change | 19.26% |
| 3 Month Change | 76.66% |
| 1 Year Change | 308.73% |
| 3 Year Change | -19.43% |
| 5 Year Change | -78.98% |
| Change since IPO | -50.04% |
Recent News & Updates
Recent updates
Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
Jan 30Corbus Pharmaceuticals GAAP EPS of -$0.11
Aug 09Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?
Nov 19
Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely
Jun 12Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?
May 14What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?
Mar 11Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?
Feb 04Corbus Pharmaceuticals: Down But Not Out
Jan 29Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?
Jan 09Corbus's lenabasum shows benefit in autoimmune disorder
Nov 09Shareholder Returns
| CRBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | 0.7% | 1.2% |
| 1Y | 308.7% | 5.0% | 27.7% |
Return vs Industry: CRBP exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: CRBP exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| CRBP volatility | |
|---|---|
| CRBP Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CRBP's share price has been volatile over the past 3 months.
Volatility Over Time: CRBP's weekly volatility has decreased from 39% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Yuval Cohen | www.corbuspharma.com |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
Corbus Pharmaceuticals Holdings, Inc. Fundamentals Summary
| CRBP fundamental statistics | |
|---|---|
| Market cap | US$474.93m |
| Earnings (TTM) | -US$33.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.0x
P/E RatioIs CRBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$23.54m |
| Gross Profit | -US$23.54m |
| Other Expenses | US$10.22m |
| Earnings | -US$33.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.4% |
How did CRBP perform over the long term?
See historical performance and comparison